All In Biotech

Drug Trial Radar · NCT06991348

Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole

Multicenter, Active-controlled, Randomized, Double-blind, Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole: TOP-GERD

Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

Jul 30, 2024

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
Carnot LaboratoriesIndustry
Sponsor type
Industry
First posted
May 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. The main question is What is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

  • TegoprazanDrug

    Tegoprazan 50 mg daily for 28 days

  • PantoprazoleDrug

    Pantoprazole 40 mg daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with resolution of the main symptoms of gastroesophageal reflux diseaseTime frame: From enrollment to the end of treatment at 4 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Gastrologen S.A. de C.V.

    Mexico City, Mexico City, Mexico · Recruiting

  • Saluz Investigación, S.C.

    Boca del Río, Veracruz, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.